Imbio RV/LV Software vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Imbio
VS
by Elucid

AI Verdict

Imbio RV/LV Software focuses on automated measurement of right and left ventricular diameters from CTPA scans to aid in risk stratification for pulmonary conditions like pulmonary embolism. In contrast, ElucidVivo A.3 provides quantitative analysis of arterial plaque composition and stability from CT angiography to assist in atherosclerosis patient stratification. While both are AI-powered cardiology and radiology imaging tools, their distinct focus areas mean they address different cardiovascular pathologies and provide complementary, rather than directly competing, diagnostic insights.

Choose Imbio RV/LV Software if…

Choose Imbio RV/LV Software if your primary need is rapid, automated assessment of right and left ventricular strain from CTPA scans. This tool is ideal for quickly calculating the RV/LV ratio to aid in risk stratification for patients presenting with acute pulmonary conditions, such as suspected pulmonary embolism, by providing automated measurements and reports without user intervention.

View Imbio RV/LV Software →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require detailed, quantitative analysis of arterial plaque composition and stability from CT angiography. This software is best suited for stratifying patients with atherosclerosis by objectively quantifying plaque components like Lipid-Rich Necrotic Core (LRNC) and providing 3D visualizations to optimize long-term treatment decisions based on plaque vulnerability.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Imbio RV/LV Software ElucidVivo A.3
Deployment Cloud-based, Locally virtualized (virtual machine, Docker), or through partners like Aidoc, Blackford Analysis, and Philips Healthcare. [9, 27] Cloud and on-premise secure deployment.
FDA Status Yes AI-estimated Cleared AI-estimated
HIPAA Unknown Yes AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Imbio RV/LV Software ElucidVivo A.3
Primary Focus Automated measurement of right and left ventricular diameters from CTPA scans for risk stratification in pulmonary conditions like pulmonary embolism. Quantitative analysis of arterial plaque composition and stability from CT angiography to assist in atherosclerosis patient stratification and optimize treatment decisions.
Company Imbio Elucid Bioimaging
Key Quantitative Analysis Automated measurement of right and left ventricular diameters, calculation and reporting of RV/LV ratio. AI-powered quantitative analysis of arterial plaque, objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, derives fractional flow reserve (FFRct).
Target Specialties Cardiology, Pulmonology, Radiology Cardiology, Radiology, Vascular Surgery

Videos

Demos, reviews, and walkthroughs featuring Imbio RV/LV Software and ElucidVivo A.3.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Imbio RV/LV Software is designed for risk stratification in pulmonary conditions, such as pulmonary embolism, by automatically measuring right and left ventricular diameters from CTPA scans and providing an RV/LV ratio. ElucidVivo A.3, on the other hand, provides quantitative analysis of arterial plaque composition and stability from CT angiography to assist physicians in atherosclerosis patient stratification and optimize treatment decisions.
Imbio RV/LV Software automatically measures right and left ventricular diameters and calculates and reports the RV/LV ratio. It also provides annotated images showing ventricular measurements and generates summary PDF reports. ElucidVivo A.3 offers AI-powered quantitative analysis of arterial plaque, objectively quantifying Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, and derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity.
Imbio RV/LV Software utilizes non-gated, contrast-enhanced CT pulmonary angiogram (CTPA) images in DICOM format as input. ElucidVivo A.3 requires CT angiography scans for its quantitative analysis of arterial plaque.
ElucidVivo A.3 explicitly states that its quantitative analysis of arterial plaque composition and stability is validated against ground-truth histology. Imbio RV/LV Software does not explicitly detail a specific validation method against a gold standard beyond being FDA cleared, though it mentions published scientific and technical peer-reviewed articles related to RV/LV analysis.
AI Tool Finder
AI-powered search. Results may not be comprehensive.